Rudolf Gygax
Director/Miembro de la Junta en The Genetics Co., Inc. .
Perfil
Rudolf Gygax is currently the Vice Chairman at The Genetics Co., Inc. He previously held positions as Chairman at Covagen AG, Managing Director at Novartis Venture Funds, Director-Supervisory Board at SynphaBase AG, and Director at Pearltec AG.
He was also a Managing Partner at Nextech Invest AG from 2012 to 2015 and a Member-Management Board at Santhera Pharmaceuticals Holding AG from 2004 to 2009.
Gygax received his undergraduate degree from Stanford University and the University of Basel.
Cargos activos de Rudolf Gygax
Empresas | Cargo | Inicio |
---|---|---|
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Rudolf Gygax.
Empresas | Cargo | Fin |
---|---|---|
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Inversor de Capital Privado | 31/01/2015 |
SANTHERA PHARMACEUTICALS HOLDING AG | Corporate Officer/Principal | 27/04/2009 |
Pearltec AG
Pearltec AG Medical SpecialtiesHealth Technology Pearltec AG develops and sells medical devices. The company specializes in medical devices for positioning and immobilizing a part of the patient’s body during medical scanning. The company was founded by Ralph Mueller, Thomas Muller, Patrizia Fischer and Mario Schmuziger in 2008 and is headquartered in Zürich, Switzerland. | Director/Miembro de la Junta | - |
SynphaBase AG
SynphaBase AG Miscellaneous Commercial ServicesCommercial Services SynphaBase AG provides contract research and development services to the pharmaceutical and chemical industry. Its products and services include route finding and process development, production of multi-kg up to metric tons, lab scale synthesis and carbohydrates and glycans. The firm’s catalogue includes monosaccharides as building blocks for glycan synthesis with various protecting group patterns and linker systems, disaccharides, oligosaccharides, glycosyl amino acids; core structures and building blocks for carbohydrate-based vaccine. The company was founded by in Arthur Bodenmüller in December 2000 and is headquartered in Pratteln, Switzerland. | Director/Miembro de la Junta | - |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Presidente | - |
Formación de Rudolf Gygax.
Stanford University | Undergraduate Degree |
University of Basel | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
Empresas privadas | 6 |
---|---|
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Finance |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Finance |
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Health Services |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
SynphaBase AG
SynphaBase AG Miscellaneous Commercial ServicesCommercial Services SynphaBase AG provides contract research and development services to the pharmaceutical and chemical industry. Its products and services include route finding and process development, production of multi-kg up to metric tons, lab scale synthesis and carbohydrates and glycans. The firm’s catalogue includes monosaccharides as building blocks for glycan synthesis with various protecting group patterns and linker systems, disaccharides, oligosaccharides, glycosyl amino acids; core structures and building blocks for carbohydrate-based vaccine. The company was founded by in Arthur Bodenmüller in December 2000 and is headquartered in Pratteln, Switzerland. | Commercial Services |
Pearltec AG
Pearltec AG Medical SpecialtiesHealth Technology Pearltec AG develops and sells medical devices. The company specializes in medical devices for positioning and immobilizing a part of the patient’s body during medical scanning. The company was founded by Ralph Mueller, Thomas Muller, Patrizia Fischer and Mario Schmuziger in 2008 and is headquartered in Zürich, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Rudolf Gygax